National Technical Reports Library

The National Technical Information Service acquires, indexes, abstracts, and archives the largest collection of U.S. government-sponsored technical reports in existence. The NTRL offers online, free and open access to these authenticated government technical reports. Technical reports and documents in its repository may be available online for free either from the issuing federal agency, the U.S. Government Publishing Office’s Federal Digital System website, or through search engines.

Details

Challenges to FDA's Ability to Monitor and Inspect Foreign Clinical Trials.

PB2010114711

Publication Date	2010
Personal Author	Levinson, D. R.
Page Count	50
Abstract	The Federal Food, Drug, and Cosmetic Act requires all new investigational drugs and biologics to undergo clinical trials on human subjects (hereinafter referred to as 'subjects') to demonstrate the safety and efficacy of these products prior to approval for sale in the United States. Through its review of the clinical trial protocol and sponsors' marketing applications and its inspections of clinical trial sites, FDA ensures the rights, safety, and well-being of subjects who participate in these trials and verifies that the clinical trial data collected are both accurate and reliable. The objectives of the research are as follows: 1. To determine the extent to which sponsors submitted data from foreign clinical trials to support drug- and biologic-marketing applications approved by the Food and Drug Administration (FDA) in fiscal year (FY) 2008. 2. To determine the extent to which FDA monitors and inspects foreign clinical trials that support marketing applications.
Keywords	Marketing applications Clinical trials Foreign countries Federal government agencies Drugs Inspections Data limitations Monitoring Biologics Humans Food and Drug Administration (FDA) Foreign clinical trials Federal Food Drug and Cosmetic Act
Source Agency	Department of Health and Human Services, Washington, DC
Corporate Authors	Department of Health and Human Services, Washington, DC. Office of the Inspector General.
Document Type	Technical Report
NTIS Issue Number	201023

Challenges to FDA's Ability to Monitor and Inspect Foreign Clinical Trials.

Challenges to FDA's Ability to Monitor and Inspect Foreign Clinical Trials.
PB2010114711

Publication Date	2010
Personal Author	Levinson, D. R.
Page Count	50
Abstract	The Federal Food, Drug, and Cosmetic Act requires all new investigational drugs and biologics to undergo clinical trials on human subjects (hereinafter referred to as 'subjects') to demonstrate the safety and efficacy of these products prior to approval for sale in the United States. Through its review of the clinical trial protocol and sponsors' marketing applications and its inspections of clinical trial sites, FDA ensures the rights, safety, and well-being of subjects who participate in these trials and verifies that the clinical trial data collected are both accurate and reliable. The objectives of the research are as follows: 1. To determine the extent to which sponsors submitted data from foreign clinical trials to support drug- and biologic-marketing applications approved by the Food and Drug Administration (FDA) in fiscal year (FY) 2008. 2. To determine the extent to which FDA monitors and inspects foreign clinical trials that support marketing applications.
Keywords	Marketing applications Clinical trials Foreign countries Federal government agencies Drugs Inspections Data limitations Monitoring Biologics Humans Food and Drug Administration (FDA) Foreign clinical trials Federal Food Drug and Cosmetic Act
Source Agency	Department of Health and Human Services, Washington, DC
Corporate Authors	Department of Health and Human Services, Washington, DC. Office of the Inspector General.
Document Type	Technical Report
NTIS Issue Number	201023